Tirofiban

Names

[ Name ]:
Tirofiban

[Synonym ]:
Tirofiban [BAN:INN]
N-(Butylsulfonyl)-O-[4-(piperidin-4-yl)butyl]-L-tyrosine
N-(n-butanesulfonyl)-O-(4-(4-piperidinyl)butyl)-(S)-tyrosine
MFCD05237246
2-S-(n-Butylsulfonylamino)-3[4-(piperidin-4-yl)butyloxyphenyl]propionic acid
(S)-2-(butane-1-sulfonylamino)-3-[4-(4-piperidin-4-yl-butoxy)phenyl]-propionic acid
Agrastat
Agrastat (TN)
N-(Butylsulfonyl)-O-[4-(4-piperidinyl)butyl]tyrosine
(2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid
UNII-GGX234SI5H
Aggrastat
Tirofiban
Tirofiban (INN)
Tyrosine, N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-
(2S)-2-(butane-1-sulfonamido)-3-{4-[4-(piperidin-4-yl)butoxy]phenyl}propanoic acid
N-(BUTYLSULFONYL)-O-[4-(4-PIPERIDINYL)BUTYL]-L-TYROSINE
L-tyrosine, N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-
L700462
MK383

Biological Activity

[Description]:

Tirofiban(L700462;MK383) is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonistTarget: integrin IIb/IIIa Tirofiban hydrochloride monohydrate blocks platelet aggregation and thrombus formation. Tirofiban is an antithrombotic used in the treatment of unstable angina.Tirofiban, in a concentration-dependent manner reduced platelet aggregation evoked by ADP (IC50 approximately 70 ng/ml), collagen (IC50 approximately 200 ng/ml), and thrombin (IC50 approximately 5,000 ng/ml).

[Related Catalog]:

Signaling Pathways >> Cytoskeleton >> Integrin

Research Areas >> Cardiovascular Disease

[References]

[1]. Winter JP, Juergens CP. The role of tirofiban in the management of coronary artery disease. Cardiovasc Hematol Disord Drug Targets. 2008 Jun;8(2):138-46.

[2]. van 't Hof AW, Valgimigli M. Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. Drugs. 2009;69(1):85-100.

[3]. Valgimigli M, Biondi-Zoccai G, Tebaldi M et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J. 2010 Jan;31(1):35-49.

[4]. Valgimigli M, Tebaldi M. Safety evaluation of tirofiban. Expert Opin Drug Saf. 2010 Sep;9(5):801-19.

[5]. Diaz JF, Cardenal R, Gomez-Manchero A, Sanchez-Gonzalez C. Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab. Cardiovasc Hematol Agents Med Chem. 2011 Jul 1;9(3):147-53.

[Related Small Molecules]

Chemical & Physical Properties

[ Density]:
1.2±0.1 g/cm3

[ Boiling Point ]:
611.7±65.0 °C at 760 mmHg

[ Melting Point ]:
223-225ºC

[ Molecular Formula ]:
C₂₂H₃₆N₂O₅S

[ Molecular Weight ]:
440.597

[ Flash Point ]:
323.7±34.3 °C

[ Exact Mass ]:
440.234497

[ PSA ]:
113.11000

[ LogP ]:
4.14

[ Vapour Pressure ]:
0.0±1.8 mmHg at 25°C

[ Index of Refraction ]:
1.532

[ Storage condition ]:
-20°C

Safety Information

[ Hazard Codes ]:
Xi

[ Risk Phrases ]:
36/37/38

[ Safety Phrases ]:
S22-S26-S30-S36/37/39-S45

[ RIDADR ]:
UN3261

[ Packaging Group ]:
II

[ Hazard Class ]:
8

[ HS Code ]:
2942000000

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

DownStream

Customs

[ HS Code ]: 2942000000